Categories Earnings, Health Care
Bausch Health Companies Inc. (NYSE: BHC): Q4 2019 Earnings Snapshot
— Bausch Health Companies Inc. (NYSE: BHC) reported a loss of $4.30 per share for the fourth quarter of 2019, compared to a loss of $0.98 per share last year, vs. $1.15 per share loss expected.
— Net loss for the quarter was $1.516 billion, compared to a loss of $344 million a year earlier
— December-quarter revenues increased 5% annually to $2.22 billion, vs. $2.2 billion expected
— Revenue of Bausch + Lomb/International, the main business segment, grew 3% annually; Salix segment revenue was up 21%
— Received FDA approval for ARAZLO Lotion for the topical treatment of acne vulgaris in young adults
— Raised capital allocation for research and development by 14% in fiscal 2019, compared to last year
— Expects full-year 2020 revenues to be in the range of $8.65 billion to $8.85 billion
— Looking for adjusted EBITDA in the range of $3.50 billion to $3.65 billion for fiscal 2020
Most Popular
AAPL Earnings: Apple Q1 revenue up 11%; earnings beat Street view
Apple Inc. (NASDAQ: AAPL) on Thursday said its first-quarter sales and earnings increased, aided by stable demand for its popular smartphone brand iPhone and strength of the services business. The
INTC Stock: Intel set to gain from stable sales, capacity expansion this year
Intel Corporation (NASDAQ: INTC) has been on an aggressive expansion drive to strengthen its foothold in the semiconductor industry. The chipmaker's recent performance indicates it has effectively tackled competition through
Microsoft (MSFT) becomes a compelling buy after strong earnings, Activision deal
Microsoft Corp. (NASDAQ: MSFT) is one of the most innovative technology companies, constantly transforming the business to align with the rapidly changing digital economy. While aggressively participating in the digital
